glp 1 drugs safe GLP-1 Agonists: A Comprehensive Overview How GLP-1 medications are transforming
Description
For example, the FLOW trial demonstrated that GLP-1 medications can slow CKD progression and lower the risk of kidney failure
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis
Results In the intention-to-treat analysis, dementia risk was not different between GLP1-RA and DPP4i initiators (hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.871.04
Advancements in drug formulations are improving patient compliance
In addition, regulatory bodies are adapting to the evolving landscape, which may facilitate faster approvals for innovative therapies
But these studies examined substances one at a time
